(Q38210239)

English

Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview.

scientific article published on 08 May 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

thromboembolism

1 reference

based on heuristic

inferred from title

macular degeneration

1 reference

based on heuristic

inferred from title

Francesco Semeraro

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Ciro Costagliola

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Mario R. Romano

5

object named as

Mario R Romano

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Francesco Morescalchi

2

object named as

Francesco Morescalchi

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

3

object named as

Sarah Duse

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Elena Gambicorti

4

object named as

Elena Gambicorti

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

language of work or name

0 references

publication date

8 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Expert Opinion on Drug Safety

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

785-802

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Anti-angiogenic therapy: rationale, challenges and clinical studies

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Vascular endothelial growth factor is a secreted angiogenic mitogen

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Mechanism of inflammation in age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

VEGF-D promotes the metastatic spread of tumor cells via the lymphatics

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Remodeling after stroke

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Expression of vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia/reperfusion injury.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

The many antithrombotic actions of nitric oxide

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Vascular endothelial growth factor is associated with histological instability of carotid plaques.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Age-related macular degeneration and risk for stroke

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

The expanding role of vascular endothelial growth factor inhibitors in ophthalmology

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Vascular endothelial growth factor (VEGF) inhibition--a critical review

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Comparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumab

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Hospitalized cardiovascular diseases in neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Bevacizumab vs ranibizumab-an appraisal of the evidence from CATT and IVAN.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Aflibercept in wet AMD: specific role and optimal use.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Pegaptanib for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Inhibitors of ocular neovascularization: promises and potential problems.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Safety in Aflibercept versus Ranibizumab

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Prevalence and impact of depressive symptoms in patients with age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Depressive symptoms and quality of life in people with age- related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Stroke and acute Myocardial Infarction in the Thrombolytic era: Clinical correlates and long-term prognosis

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.911284

21 January 2018

Identifiers

10.1517/14740338.2014.911284

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

release_pvoiyae6h5gmze7hke2ayo2gkq

1 reference

https://api.fatcat.wiki/v0/release/pvoiyae6h5gmze7hke2ayo2gkq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809388%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38210239&oldid=2168259812"